Jupiter Topco LLC Invests $101.76 Million in Maze Therapeutics, Inc. $MAZE

Jupiter Topco LLC bought a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE) during the second quarter, Holdings Channel reports. The fund bought 3,408,045 shares of the company’s stock, valued at approximately $101,764,000. Jupiter Topco LLC owned about 0.06% of Maze Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. TRV GP IV LLC acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at $133,502,907,000. ARCH Venture Management LLC purchased a new stake in Maze Therapeutics during the second quarter valued at about $122,983,582,000. BlackRock Inc. purchased a new stake in Maze Therapeutics during the second quarter valued at about $104,525,000. Janus Henderson Group PLC boosted its holdings in shares of Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Maze Therapeutics by 27.1% in the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after buying an additional 362,060 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on MAZE shares. BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Price Performance

NASDAQ MAZE opened at $29.58 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -11.74 and a beta of 2.21. The company has a 50 day simple moving average of $28.64 and a 200-day simple moving average of $32.04. Maze Therapeutics, Inc. has a 52-week low of $13.67 and a 52-week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). Equities research analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Insider Activity

In related news, CMO Harold Bernstein sold 16,142 shares of Maze Therapeutics stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the sale, the chief marketing officer owned 16,142 shares of the company’s stock, valued at approximately $445,680.62. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total value of $205,050.00. Following the sale, the insider directly owned 26,250 shares of the company’s stock, valued at approximately $717,675. The trade was a 22.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 108,110 shares of company stock worth $3,057,531 in the last ninety days. Corporate insiders own 5.30% of the company’s stock.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.